|
View previous topic :: View next topic |
Author |
Message |
agate Site Admin
Joined: 17 May 2006 Posts: 5694 Location: Oregon
|
Posted: Fri Jun 14, 2013 6:07 pm Post subject: (Summary) MRI lesions as [markers] for MS relapses |
|
|
From Lancet Neurology, July 2013:
Quote: |
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Dr Maria Pia Sormani PhD a , Paolo Bruzzi MD b
Background
A meta-analysis of randomised trials in relapsing-remitting multiple sclerosis published in 2009 showed a quantitative relation between the treatment effects detected on MRI lesions and clinical relapses. We aimed to validate that relation using data from a large and independent set of clinical trials in multiple sclerosis.
Methods
We searched Medline for clinical trials that assessed disease-modifying drugs for relapsing-remitting multiple sclerosis published from Sept 1, 2008, to Oct 31, 2012. We extracted data for the treatment effects on MRI lesions and on relapses from each trial, and the correlation of log transformed relative measures of these treatment effects was assessed with a weighted linear regression analysis. The R2 value was estimated to quantify the strength of the correlation, and we used an interaction test to test for a difference in slope from the previously estimated equation. We also ran several sensitivity analyses.
Findings
We identified 31 eligible trials, which provided data for 18,901 patients with relapsing-remitting multiple sclerosis. The regression equation derived using data from these studies showed a relation between the concurrent treatment effects on MRI lesions and relapses (slope=0·52; R2=0·71), much the same as was previously estimated (pinteraction=0·45). Analysis of trials that tested the same drugs in phase 2 and phase 3 studies showed that the effects on MRI lesions over short follow-up periods (6—9 months) can also predict the effects on relapses over longer follow-up periods (12—24 months), with reported effects on relapses that were within the 95% prediction intervals in eight of nine trials.
Interpretation
Our findings indicate that the effect of a treatment on relapses can be accurately predicted by the effect of that therapy on MRI lesions, implying that the use of MRI markers as primary endpoints in future clinical trials of treatments for multiple sclerosis can be considered, in specific situations, such as in trials testing generics or biosimilars of drugs with a well known mechanism of action or in paediatric trials testing drugs already approved for adults.
__________________________
Funding:
None.
|
|
|
Back to top |
|
|
|
|
You can post new topics in this forum You can reply to topics in this forum You can edit your posts in this forum You can delete your posts in this forum You cannot vote in polls in this forum
|
|
|